InvestorsHub Logo
Followers 105
Posts 4947
Boards Moderated 0
Alias Born 10/20/2015

Re: anders2211 post# 258676

Saturday, 07/11/2020 3:32:46 PM

Saturday, July 11, 2020 3:32:46 PM

Post# of 457596
Actually ASXM is expanding indications into PDD and others with new trials planned. Axsome however has a Vescepa problem in that it has a shallow moat being a combination of two generics. Others could trial a better drug like Zoloft with SR1 DM ...two generics. Or better yet a patented SR1 like blarcamesine with bupropion. Especially once blarcamesine is approved for anything else.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News